# Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer

> **NCT00578149** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 45 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00578149
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2007-12-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00578149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00578149, "Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00578149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*